Novel Glaucoma Diagnostics

StatusRecruiting
PhaseNot specified
SponsorWills Eye
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: NYU Langone Health to Wills Eyev21 Show 6 more changesShow less
    • Enrollment target: 1322 to 5000
    • Primary and study completion dates pushed to Jul 31, 2029
    • Start date: Jan 1995 to Aug 1, 2000
    • Trial status: Completed to Recruiting
    • Study site revised
    • Study title shortened, about 2 words
  2. Primary endpoint revised
    • Eligibility criteria expanded, about 72 words
    • Study description expanded, about 24 words
    v20
  3. Trial status: Recruiting to Completedv19 Show 4 more changesShow less
    • Enrollment target: estimated 2767 to confirmed 1322
    • Primary completion date changed from estimate of Jan 2024 to Aug 10, 2023
    • Study completion date changed from estimate of Jan 2025 to Feb 19, 2024
    • Site details revised
  4. Re-verified, no change to tracked fieldsv18
  5. Site contact updatedv17
Show 15 earlier versionsHide 15 earlier versions
  1. 2 versions Re-verified since Jul 12, 2021, no change to tracked fieldsv15-v16
  2. Primary completion date: Jan 2020 to Jan 2024
    • Study completion date: Jan 2020 to Jan 2025
    v14
  3. Trial status: Active, Not Recruiting to Recruiting
    • Site details revised
    v13
  4. Primary completion date: May 2018 to Jan 2020v12
  5. Primary completion date: Jan 2018 to May 2018
    • Study site revised
    v11
  6. Re-verified, no change to tracked fieldsv10
  7. Lead sponsor: University of Pittsburgh to NYU Langone Healthv9 Show 7 more changesShow less
    • Primary completion date: May 2017 to Jan 2018
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 500 to confirmed 2767
    • Study completion date: Jun 2017 to Jan 2020
    • Study description expanded, about 498 words
    • Site details revised
    • Collaborator revised
  8. Re-verified, no change to tracked fieldsv8
  9. Primary completion date: May 2012 to May 2017
    • Study completion date: May 2012 to Jun 2017
    v7
  10. Primary and study completion dates: May 2012
    • Site contact updated
    v6
  11. Re-verified, no change to tracked fieldsv5
  12. Eligibility criteria shortened, about 6 words
    • Site contact updated
    v4
  13. 2 versions Re-verified since Sep 8, 2006, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Wills Eye
5 trials monitored
See all monitored trials
Diabetes
5,133 trials monitored
See 238 trials at risk
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases
Trial Details
NCT Number NCT00286637
Lead Sponsor Wills Eye
Collaborators: National Eye Institute (NEI)
Conditions
(from sponsor)		 Glaucoma, Macular Disease
Related terms Diabetes Mellitus, Glaucoma, Macular Degeneration, Retinal Diseases, Retinal Perforations
Enrollment 5,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov